The USA pharmaceutical industry is seriously affected as President Trump issued a 100% tariff on foreign branded medicines imported from overseas, which became effective from October 1, unless manufacturers initiate U.S. production. The policy can lead to higher prices and shortages of life-saving medications, including Levocetirizine Dihydrochloride, which is widely used to treat allergic disorders. Last year alone, the U.S. imported nearly USD 252 billion of medicines, primarily from Europe and Asia, and the sector could face pressures from tariffs. Experts estimate that the fourth quarter of 2025 might witness spectacular price hikes in Levocetirizine Dihydrochloride as importers come to terms with new tariffs. Low-volume wholesalers may experience narrower profit margins and inventory issues. While some pharmaceutical companies have committed USD 300 million towards US factory investments, constructing factories is a slow process, interfering with quick tariff relief. The impending October 1 deadline is a turning point for the pharmaceutical market, possibly reframing supply chains and pricing structures. With costs increasing, healthcare professionals warn patients that they will pay more for treatment, highlighting the war between trade policy and healthcare affordability.
